Simple Summary Glioblastoma multiforme (GBM) is one of the most aggressive
malignancies, accounting for 14.5% of all central nervous system tumors and 48.6% of …

Isocitrate dehydrogenase (IDH) mutant gliomas are the most common adult, malignant
primary brain tumors diagnosed in patients younger than 50, constituting an important cause …

The WHO 2007 glioma classification system (based primarily on tumour histology) resulted
in considerable interobserver variability and substantial variation in patient survival within …

Glioblastoma (GBM) is a rare tumor and one of the most challenging malignancies to treat in
all of oncology. Although advances have been made in the treatment of GBM, encouraging …

Glioblastoma multiforme (GBM) is the most common and aggressive primary central nervous
system malignancy with a median survival of 15 months. The average incidence rate of GBM …

Purpose: Lower-grade gliomas (WHO grade II/III) have been classified into clinically relevant
molecular subtypes based on IDH and 1p/19q mutation status. The purpose was to …

Gliomas are the most common malignant primary brain tumours in adults and cannot usually
be cured with standard cancer treatments. Gliomas show intratumoural and intertumoural …

ABSTRACT Isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are key metabolic enzymes,
converting isocitrate to α-ketoglutarate (αKG). IDH1 and IDH2 mutations have been …

Glioblastoma is the most frequent and malignant brain tumor. The vast majority of
glioblastomas (∼ 90%) develop rapidly de novo in elderly patients, without clinical or …

Patients with glioblastoma (GBM) have a universally poor prognosis and are in urgent need
of effective treatment strategies. Recent advances in sequencing techniques unraveled the …